Premier Biomedical Advances New Cancer Treatment Methodology Protocol
Premier Biomedical Inc. (OTC: BIEI) has made significant progress over the past month advancing the development of its anti-CLA4-based cancer treatment methodology protocol. After moving to patent the approach, the company’s partners presented at one of the most prestigious cancer research organizations in the United States, bringing heightened attention to the company.
In this article, we’ll take a look at the presentation, potential new approaches in development, and what it all means for investors.
Promising Research
In April, researchers at the University of Texas El Paso (“UTEP”) presented positive results from its duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego. The results showed statistically significant improvements in survival and prevention of breast cancer in mice treated with its anti-breast cancer treatment versus chemotherapy-only and non-treated groups.
“This represents a major step forward in the goal of preventing breast cancer metastasis and defeating cancer in a completely nontoxic manner by utilizing the body’s own immune system,” said Dr. Mitchell S. Felder, Chairman of Premier Biomedical’s Scientific Advisory Board. “The AACR conference is one of the most prestigious venues in the world for presenting cutting-edge cancer research.”
According to a recent interview Premier Biomedical CEO William A. Hartman, the company’s anti-CTLA4-based cancer treatment is similar to Bristol-Myers Squibb’s (NYSE: BMY) YERVOY (“ipilimumab”), but has an additional immune system component that’s unique within the industry. Management also believes that the approach could be used in many different forms of cancer beyond just breast cancer.
New Developments
In April, Premier Biomedical prepared and planned to file a provisional patent application for its anti-breast cancer treatment methodology protocol in conjunction with the U.S. Department of Defense and University of Texas El Paso. The group also plans to initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are both unique and promising.
“We understand that a lot of research has to be accomplished on these new treatments, but we have developed the planned test procedures and have approved funding to proceed at full speed,” said Mr. Hartman. “Because of our R&D relationships with the DoD and UTEP, we have the organizational flexibility to respond quickly and seamlessly to increased workload and new projects.”
With the possibility of being effective against “a range of cancer types”, the two new cancer treatment approaches under development could significantly expand the company’s addressable market size. Cancer.org estimates that approximately 1,665,540 new cases of cancer will be diagnosed in the U.S. 2014, while about 13.7 million U.S. citizens are alive that have a history of cancer.
Potential Upside
Premier Biomedical trades with a market capitalization of approximately $10.7 million, with numerous potential venues to achieve higher revenues and profits down the road. In addition to its focus on cancer research, the company’s sequential dialysis technology could also become game-changers for other conditions, ranging from traumatic brain injury (“TBI”) to Alzheimer’s disease.
These potential indications put the company in the same business as other publicly-traded stocks like Merck & Co. Inc. (NYSE: MRK) taking on Alzheimer’s disease and Abbott Inc. (NYSE: ABT) using monoclonal antibodies to target cancer. If management is successful in bringing its technologies to market, the company could become an acquisition target for firms like these looking to bolster their portfolios.
For more information, visit the following resources:
- Company Website
- OTC Markets Profile
Get Updates on Premier Biomedical here: http://www.tdmfinancial.com/emailassets/biei/biei_landing.php
Disclosure:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx